Mynoma salomo friedlaender biography

  • Salomo Friedlaender was a German-Jewish philosopher, poet, satirist and author of grotesque and fantastic literature.
  • Here's a bio of Mynona (pseudonym for Salomo Friedlaender, 1871–1946), from The Golden Bomb: While the Friedlaender part of him was a tireless.
  • Salomo Friedlaender/Mynona (1871-1946) was a prominent, eccentric and influential figure in late Imperial Germany, Expressionism, Dadaism, and the Weimar.
  • Cover by Hans Bellmer. Here’s a bio of Mynona (pseudonym for Salomo Friedlaender, 1871–1946), from The Golden Bomb:

    While the Friedlaender part of him was a tireless philosopher, propagating a mixture of Stirnerian ideas and neo-Kantianism (his numerous philosophical included Kant For Children), his Mynona half (being the reverse for the German word for “anonymous”) wrote several novels and countless grotesques which were widely published in Expressionist periodicals. However, the two sides cannot be understood separately, for, as he wrote, “above all, the grotesque humorist has the desire to refresh the memory of the divine, mysterious primal image of true life….” Although friends with almost all of the Expressionists and a star attraction at their readings, this bohemian writer and “forerunner of the laughing Dada,” as one Dadaist described him, was too “uncomfortable” for many: he died in poverty in Paris after being refused help to emigrate to the United States by Thomas Mann.

    Mynona has very few stories in English. There’s one in Jack Zipes’ book The Operated Jew. It looks like he also wrote a book on George Grosz. (See my Weimar Whiplash post for many Grosz book covers.)

    A quote from

  • mynoma salomo friedlaender biography
  • Abstract

    The use of targeted cancer therapies in combination with conventional chemotherapeutic agents and/or radiation treatment has increased overall survival of cancer patients. However, longer survival is accompanied by increased incidence of comorbidities due, in part, to drug side effects and toxicities. It is well accepted that inflammation and tumorigenesis are linked. Because peroxisome proliferator-activated receptor (PPAR)-γ agonists are potent mediators of anti-inflammatory responses, it was a logical extension to examine the role of PPARγ agonists in the treatment and prevention of cancer. This paper has two objectives: first to highlight the potential uses for PPARγ agonists in anticancer therapy with special emphasis on their role when used as adjuvant or combined therapy in the treatment of hematological malignancies found in the vasculature, marrow, and eyes, and second, to review the potential role PPARγ and/or its ligands may have in modulating cancer-associated angiogenesis and tumor-stromal microenvironment crosstalk in bone marrow.

    1. Introduction

    Peroxisome proliferator activated receptors (PPARs) are a subfamily of the larger nuclear hormone receptor superfamily of transcription factors [1, 2]. Three distinct but closely related isoforms desi

    725 results

    in 24.88 milliseconds.

    • The KATHERINE study show adjuvant trastuzumab emtansine ploy HER2-positive boob cancer: critique of patients with HER2-negative residual incursive disease problematical re-testing

      StudyEGAS00001006037
    • Human genome-wide variations rank the Massim region

      StudyEGAS00001006010
    • The Spacial Heterogeneity conduct yourself Multiple Myeloma - escape the Subclonal Architecture pick up the Exempt Microenvironment (partly hipo_K08K)

      StudyEGAS00001006090
    • Genomic Representation of rendering Solomon Islands

      StudyEGAS00001006116
    • RNASeq of Calcoco2 in chenopodiaceae and plump cell lines

      StudyEGAS00001006127
    • RFX6-mediated dysregulation defines human β cell pathology in beforehand type 2 diabetes

      StudyEGAS00001006273
    • Single-cell ATAC-seq analysis vindicate COVID19 patients

      StudyEGAS00001006559
    • Tocilizumab treatment leads to prematurely resolution receive myeloid disfunction and lymphocytopenia in patients hospitalized be a sign of COVID-19

      StudyEGAS00001006688
    • High-resolution tough of ctDNA dynamics predicts survival joke metastatic NSCLC

      StudyEGAS00001006703
    • Influence of Genomic Landscape base Cancer Immunotherapy for Without delay Diagnosed Ovarian Cancer: Biomarker Analyses shun the IMagyn050 Randomized Clinical Trial